Toji Tomohiro, Takata Katsuyoshi, Sato Yasuharu, Miyata-Takata Tomoko, Hayashi Eiko, Habara Toshiyuki, Maeda Yoshinobu, Tanimoto Mitsune, Yoshino Tadashi
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Department of Pathology, Iwakuni Medical Center, Iwakuni, Japan.
J Clin Pathol. 2015 Aug;68(8):622-7. doi: 10.1136/jclinpath-2015-202934. Epub 2015 May 2.
Acute lymphoblastic leukaemia/lymphoma (ALL/LBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) affecting B-cells or T-cells, respectively. The serum level of soluble interleukin-2 receptor (sIL-2R) is known to reflect the immune activity and tumour volume in aggressive NHL; however, the release of sIL-2R in LBL has not been extensively studied. Further, the relationship between sIL-2R release and the expression level of IL-2R α subunit (CD25) remains unknown. In the present study, we examined the serum level of sIL-2R in 23 patients with T lymphoblactic lymphoma (T-LBL) and compared these with the levels in 20 patient with T acute lymphoblastic leukaemia (T-ALL), 40 patients with diffuse large B-cell lymphoma (DLBCL) and 40 patients with peripheral T-cell lymphoma (PTCL), not otherwise specified. The release of sIL-2R into the serum in patients with T-LBL was significantly lower than that for T-ALL, DLBCL and PTCL (p<0.001). Immunohistochemistry revealed that CD25 expression was correlated with the serum level of sIL-2R in T-LBL (p=0.0069), whereas no correlation was found to exist between serum sIL-2R levels and CD25 expression in patients with DLBCL (p=0.348) and PTCL (p=0.266). Furthermore, double immunohistochemical analysis revealed that CD25-positive cells were also found to be Foxp3-positive non-neoplastic T-cells. In conclusion, CD25-positive non-neoplastic T-cells in T-LBL are presumed to be the primary source of sIL-2R, and the low number of cells present results in a lower level of sIL-2R released into the serum compared with the other aggressive and highly aggressive lymphomas.
急性淋巴细胞白血病/淋巴瘤（ALL/LBL）是一种侵袭性非霍奇金淋巴瘤（NHL），分别影响B细胞或T细胞。已知可溶性白细胞介素-2受体（sIL-2R）的血清水平可反映侵袭性NHL中的免疫活性和肿瘤体积；然而，sIL-2R在LBL中的释放尚未得到广泛研究。此外，sIL-2R释放与白细胞介素-2受体α亚基（CD25）表达水平之间的关系仍然未知。在本研究中，我们检测了23例T淋巴母细胞淋巴瘤（T-LBL）患者的血清sIL-2R水平，并将其与20例T急性淋巴细胞白血病（T-ALL）患者、40例弥漫性大B细胞淋巴瘤（DLBCL）患者和40例未另行指定的外周T细胞淋巴瘤（PTCL）患者的水平进行比较。T-LBL患者血清中sIL-2R的释放明显低于T-ALL、DLBCL和PTCL患者（p<0.001）。免疫组织化学显示，T-LBL中CD25表达与血清sIL-2R水平相关（p=0.0069），而DLBCL患者（p=0.348）和PTCL患者（p=0.266）的血清sIL-2R水平与CD25表达之间未发现相关性。此外，双重免疫组织化学分析显示，CD25阳性细胞也为Foxp3阳性的非肿瘤性T细胞。总之，T-LBL中CD25阳性的非肿瘤性T细胞被认为是sIL-2R的主要来源，与其他侵袭性和高度侵袭性淋巴瘤相比，其细胞数量较少导致血清中释放的sIL-2R水平较低。
